A new review makes the clinical case for ANGPTL-axis therapeutics in dyslipidemia, while two mechanism papers add fresh evidence that ANGPTL4 drives drug resistance and inflammation in solid tumors — no adipose-targeted RNA delivery papers surfaced this cycle.

Three new mechanistic papers this week converge on ANGPTL4 as a secreted signal that drives fibrosis and immune evasion outside its classic lipid-metabolism role — in kidney, liver tumor stroma, and now the blood-brain barrier — while no new adipose-targeted RNA-delivery papers or patents cleared the bar.

A thin but focused week — ANGPTL4 surfaces in a gut-microbiome/adipose crosstalk review and in a mechanistic study linking YAP condensates to proangiogenic ANGPTL4 expression, while an adipocyte cell-death study employs adipocyte-specific siRNA to implicate caspase-8 in adipogenesis.

A thin week for direct ANGPTL4 therapeutics, but a standout paper demonstrates that circular RNA delivered via lipid nanoparticles can drive sustained GDF15-mediated fat burning in obese mice — a proof-of-concept for RNA-LNP therapies targeting adipose metabolism.

A thin week on the primary beat — two correspondence letters debate ANGPTL4 as a stroke biomarker, while two independent studies use siRNA knockdown in human and porcine adipose-derived stem cells to probe fat biology, reinforcing the utility of RNA tools in adipose tissue.

ANGPTL4 emerges prominently as a therapeutic target in a landmark Circulation Research review of triglyceride-rich lipoprotein metabolism and cardiovascular risk in diabetes, while new work in adipocyte biology highlights PPARγ-mediated transcriptional programs and antiadipogenic peptide mechanisms with direct ANGPTL4 relevance.

Three new papers this week illuminate ANGPTL4's role in tumor microenvironments, adipose-driven metabolic dysfunction in heart failure, and as an early-life obesity biomarker; no new adipose RNA delivery papers appeared in the lookback window.

Intestinal ANGPTL4 emerges as a diet-and-microbiome integrator driving gut barrier dysfunction in early fatty liver disease, while new ionizable-lipid LNP platforms continue to expand the toolkit for tissue-selective RNA delivery beyond the liver.

This week's literature shows ANGPTL4 emerging as a multi-context tumor suppressor in head and neck cancer and a ferroptosis regulator in lung injury, while Mendelian randomization studies strengthen its causal standing in metabolic-cardiovascular disease; LNP delivery science advances on bone-marrow and lung-tumor fronts but adipose-selective RNA targeting remains an active gap.

A large LURIC cohort analysis ties CD-ANGPTL4 to heart failure incidence and mortality, an OPSCC study reframes ANGPTL4 as a tumor suppressor in head-and-neck cancer, and a Cardiovascular Diabetology review flags ANGPTL4 inhibition as a candidate combination therapy for diabetic vascular complications. Patent search is offline this week.